|
Entremed Inc - Company Profile Snapshot
| Company Profile: |
Entremed Inc |
| Ticker: |
ENMD |
| Exchanges: |
NAS |
| 2008 Sales: |
7,477,200 |
| Major Industry: |
Miscellaneous |
| Sub Industry: |
Service Organizations |
| Country: |
UNITED STATES |
| Employees: |
21 |
Business Description
Entremed Inc. The Group's principal activity is to sponsor and conduct research and development of therapeutics primarily for the treatment of cancer. The Group focuses primarily on the clinical development of ENMD-2076, a novel, orally-active, kinase inhibitor with potent activity towards Aurora A and multiple other kinases linked to angiogenesis and cellular proliferation. ENMD-2076 is currently in Phase 1 clinical trials for advanced solid tumors and multiple myeloma. In addition to ENMD-2076, multiple Phase 1 and 2 clinical trials are currently underway with MKC-1, a novel cell cycle inhibitor and ENMD-1198, a novel antimitotic agent. The Group also holds an active IND for the development of 2ME2 in rheumatoid arthritis. The Group is seeking strategic alliances, licensing relationships and co-development partnerships with other companies to develop compounds for both oncology and non-oncology therapeutic areas. The Group operates in the United States.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
